Investigators: Prof Frances Boyle, Prof Max Bulsara, A/Prof Mary Haines, Asst/Prof Anna Kemp (CI), Prof David Preen, A/Prof Libby Roughead.
Selective estrogen receptor modulators (SERMs) are the cornerstone of post-surgical breast cancer treatment for women with receptor-positive tumours. Little is known, however, about the way SERMs are prescribed and used in Australian clinical practice. This project will examine issues including patient characteristics in relation to initial prescription, switching between SERMs and adherence rates. The study will also determine rates of recurrence of breast cancer and mortality for women using different SERMs in clinical practice.
